Log in

TSE:ASPAcerus Pharmaceuticals Stock Price, Forecast & News

C$0.06
0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.06
Now: C$0.06
C$0.06
50-Day Range
C$0.04
MA: C$0.05
C$0.07
52-Week Range
C$0.04
Now: C$0.06
C$0.15
Volume7,000 shs
Average Volume562,996 shs
Market CapitalizationC$60.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Read More
Acerus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone416-679-0771

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.75 million
Cash FlowC$0.02 per share
Book ValueC$0.01 per share

Profitability

Miscellaneous

Employees29
Outstanding Shares1,010,456,000
Market CapC$60.63 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive ASP News and Ratings via Email

Sign-up to receive the latest news and ratings for ASP and its competitors with MarketBeat's FREE daily newsletter.

Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions

How has Acerus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Acerus Pharmaceuticals' stock was trading at C$0.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASP shares have increased by 33.3% and is now trading at C$0.06. View which stocks have been most impacted by Coronavirus.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Acerus Pharmaceuticals.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (TSE:ASP) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.20 million during the quarter. View Acerus Pharmaceuticals' earnings history.

Has Acerus Pharmaceuticals been receiving favorable news coverage?

Media coverage about ASP stock has trended somewhat negative on Saturday, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutAcerus Pharmaceuticals.

Who are some of Acerus Pharmaceuticals' key competitors?

What other stocks do shareholders of Acerus Pharmaceuticals own?

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the following people:
  • Dr. Nathan Bryson, Chief Scientific Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Edward Gudaitis, Pres , CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer
  • Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Acerus Pharmaceuticals' stock price today?

One share of ASP stock can currently be purchased for approximately C$0.06.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of C$60.63 million and generates C$1.75 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is www.aceruspharma.com.

How can I contact Acerus Pharmaceuticals?

The company can be reached via phone at 416-679-0771.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.